



SUVEN LIFE SCIENCES LIMITED

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvan.com website: www.suvan.com

STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30th SEPTEMBER 2017

All amounts in Indian Rupees in lakhs

| Sl. No. | Particulars | For the Quarter ended | | | For the Six Months ended | | For the Year Ended |
|------------|--|-----------------------|------------------|------------------|--------------------------|------------------|--------------------|
| | | 30-Sep-2017 | 30-Jun-2017 | 30-Sep-2016 | 30-Sep-2017 | 30-Sep-2016 | 31-Mar-2017 |
| | | Un-audited | Un-audited | Un-audited | Un-audited | Un-audited | Audited |
| 1 | Revenue from operations | | | | | | |
| | (a) Net sales/income from operations (Refer Note 3) | 10,409.95 | 13,744.90 | 11,554.97 | 24,154.85 | 24,877.67 | 53,916.74 |
| | (b) Other operating income | 275.93 | 357.00 | - | 632.93 | - | 531.04 |
| | Total Revenue from operations | 10,685.88 | 14,101.90 | 11,554.97 | 24,787.78 | 24,877.67 | 54,447.78 |
| 2 | Other Income | 513.23 | 562.29 | 675.55 | 1,075.52 | 1,125.25 | 2,109.25 |
| | Total Income (1+2) | 11,199.11 | 14,664.19 | 12,230.52 | 25,863.30 | 26,002.92 | 56,557.03 |
| 3 | Expenses | | | | | | |
| | (a) Cost of materials consumed | 4,218.13 | 3,683.53 | 3,406.61 | 7,901.66 | 7,392.59 | 15,480.66 |
| | (b) Purchases of stock-in-trade | - | - | - | - | - | - |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (3,189.36) | (227.17) | (885.88) | (3,416.53) | (922.65) | (295.94) |
| | (d) Employee benefits expense | 1,267.76 | 1,566.22 | 1,201.06 | 2,833.98 | 2,348.02 | 5,064.46 |
| | (e) Finance costs | 93.58 | 127.01 | 123.73 | 220.59 | 283.29 | 566.58 |
| | (f) Depreciation and amortisation expenses | 533.99 | 519.20 | 455.22 | 1,053.19 | 935.80 | 2,141.31 |
| | (g) Manufacturing expenses | 2,101.03 | 2,190.37 | 1,909.16 | 4,291.40 | 3,650.20 | 8,157.37 |
| | (h) Research & Development expenses | 1,166.13 | 1,601.19 | 1,465.36 | 2,767.32 | 2,934.37 | 6,494.09 |
| | (i) Other expenses | 622.66 | 759.06 | 770.61 | 1,381.72 | 1,443.68 | 3,012.81 |
| | Total expenses | 6,813.92 | 10,219.41 | 8,445.87 | 17,033.33 | 18,065.30 | 40,621.34 |
| 4 | Profit before exceptional items and tax (1+2-3) | 4,385.19 | 4,444.78 | 3,784.65 | 8,829.97 | 7,937.62 | 15,935.69 |
| 5 | Exceptional Items | - | - | - | - | - | - |
| 6 | Profit before tax (4 - 5) | 4,385.19 | 4,444.78 | 3,784.65 | 8,829.97 | 7,937.62 | 15,935.69 |
| 7 | Tax Expenses | | | | | | |
| | (a) Current tax | 592.11 | 1,132.77 | 1,295.82 | 1,724.88 | 2,182.13 | 3,275.07 |
| | (b) Deferred tax | 618.35 | 354.94 | (166.89) | 973.29 | (157.84) | 313.25 |
| 8 | Net Profit for the period / year (6-7) | 3,174.73 | 2,957.07 | 2,655.72 | 6,131.80 | 5,913.33 | 12,347.37 |
| 9 | Other Comprehensive Income | | | | | | |
| 9.A | (i) Items that will not be reclassified to profit or loss | (3.72) | (3.73) | (11.31) | (7.45) | (22.61) | (14.90) |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | 1.29 | 1.29 | - | 2.58 | - | 5.15 |
| 9.B | (i) Items that will be reclassified to profit or loss | - | - | - | - | - | - |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - | - |
| | Total Other Comprehensive Income | (2.43) | (2.44) | (11.31) | (4.87) | (22.61) | (9.75) |
| | Total Comprehensive Income (8+9) | 3,172.30 | 2,954.63 | 2,644.41 | 6,126.93 | 5,890.72 | 12,337.62 |
| 10 | Paid-up equity share capital (face value of Rs. 1/- each) | 1,272.82 | 1,272.82 | 1,272.82 | 1,272.82 | 1,272.82 | 1,272.82 |
| 11 | Earning Per Share (EPS) for continuing operation (face value of Rs.1/- each): | | | | | | |
| | a) Basic | 2.49 | 2.32 | 2.08 | 4.81 | 4.63 | 9.69 |
| | b) Diluted | 2.49 | 2.32 | 2.08 | 4.81 | 4.63 | 9.69 |

See accompanying notes to the financial statements

SEGMENT WISE REVENUE, RESULTS TOTAL ASSETS AND LIABILITIES

| PARTICULARS | For the Quarter Ended | | | For the Six Months ended | | For the Year Ended |
|--|-----------------------|------------------|------------------|--------------------------|------------------|--------------------|
| | 30-Sep-2017 | 30-Jun-2017 | 30-Sep-2016 | 30-Sep-2017 | 30-Sep-2016 | 31-Mar-2017 |
| | Un-audited | Un-audited | Un-audited | Un-audited | Un-audited | Audited |
| 1 SEGMENT REVENUE | | | | | | |
| a) Manufacturing (CRAMS) | 10,026.47 | 13,330.76 | 10,705.18 | 23,357.23 | 23,471.57 | 51,670.07 |
| b) Services (DDDSS) | 659.41 | 771.14 | 849.79 | 1,430.55 | 1,406.10 | 2,777.71 |
| c) Research & Development | - | - | - | - | - | - |
| Total | 10,685.88 | 14,101.90 | 11,554.97 | 24,787.78 | 24,877.67 | 54,447.78 |
| Less: Inter Segment Revenue | - | - | - | - | - | - |
| Net Sales/Income from Operations | 10,685.88 | 14,101.90 | 11,554.97 | 24,787.78 | 24,877.67 | 54,447.78 |
| 2 SEGMENT RESULTS (Profit/(Loss) before tax and interest) | | | | | | |
| a) Manufacturing (CRAMS) | 5,312.13 | 5,782.86 | 4,696.59 | 11,094.99 | 10,293.35 | 21,634.85 |
| b) Services (DDDSS) | 319.36 | 405.25 | 503.30 | 724.61 | 761.98 | 1,476.81 |
| c) Research & Development | (1,166.14) | (1,601.18) | (1,465.36) | (2,767.32) | (2,934.37) | (6,494.09) |
| TOTAL | 4,465.35 | 4,586.93 | 3,734.53 | 9,052.28 | 8,120.96 | 16,617.57 |
| Less: i) Finance Cost | 74.19 | 87.11 | 94.99 | 161.30 | 208.25 | 376.38 |
| ii) Other Un-allocable expenditure /(income), net | 5.97 | 55.04 | (145.11) | 61.01 | (24.91) | 305.50 |
| Total Profit Before Tax | 4,385.19 | 4,444.78 | 3,784.65 | 8,829.97 | 7,937.62 | 15,935.69 |
| 3 SEGMENT ASSETS : | | | | | | |
| a) Manufacturing (CRAMS) | 53,711.58 | 47,190.09 | 43,759.56 | 53,711.58 | 43,759.56 | 43,886.93 |
| b) Services (DDDSS) | 4,077.86 | 3,511.49 | 3,598.93 | 4,077.86 | 3,598.93 | 2,828.60 |
| c) Research & Development | 2,896.37 | 2,540.08 | 2,504.29 | 2,896.37 | 2,504.29 | 2,609.60 |
| d) Un allocated | 35,647.25 | 37,517.52 | 33,044.05 | 35,647.25 | 33,044.05 | 38,291.82 |
| TOTAL | 96,333.06 | 90,759.18 | 82,906.83 | 96,333.06 | 82,906.83 | 87,616.95 |
| 4 SEGMENT LIABILITIES : | | | | | | |
| a) Manufacturing (CRAMS) | 9,984.93 | 8,830.42 | 8,201.56 | 9,984.93 | 8,201.56 | 8,547.86 |
| b) Services (DDDSS) | 574.83 | 428.06 | 400.87 | 574.83 | 400.87 | 370.23 |
| c) Research & Development | 2,253.38 | 1,873.25 | 1,826.23 | 2,253.38 | 1,826.23 | 1,848.18 |
| d) Un allocated | 925.47 | 722.22 | 684.80 | 925.47 | 684.80 | 687.23 |
| TOTAL | 13,738.61 | 11,853.95 | 11,113.46 | 13,738.61 | 11,113.46 | 11,453.50 |

Notes:

- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 11th November, 2017 and the same reviewed by the Statutory Auditors.
- Excise duty on sales was included under Revenue from operations and disclosed separately under expenses upto all reporting periods ending 30-June-2017. Post implementation of Goods and Service Tax (GST) Act w.e.f. 1st July, 2017 the revenue from operations is reported from the quarter ended 30-Sept-2017 are net of GST and hence to that extent not comparable.
- The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD

Place: Hyderabad
Date: 11th November, 2017

VENKAT JASTI
Chairman & CEO
DIN: 00278028

We Deliver